Pfizer Inc. $PFE Shares Sold by New York State Teachers Retirement System

Key Points

• New York State Teachers Retirement System trimmed its Pfizer stake by 1.9% in Q4, selling 90,733 shares and now holds 4,663,998 shares worth about $116.13 million (≈0.08% of the company).
• Pipeline and legal positives include a late‑stage trial win for ELREXFIO, a patent settlement that effectively extends VYNDAMAX U.S. protection to 2031, and FDA priority‑review acceptance of a supplemental BLA for PADCEV, supporting near‑ and longer‑term revenue prospects.
• Pfizer beat Q4 estimates with $0.66 EPS (vs. $0.57 consensus) and $17.56B revenue, and announced a $0.43 quarterly dividend (annualized $1.72) representing a 6.4% yield, with ex‑dividend on May 8 and payment June 12.

New York State Teachers Retirement System decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,663,998 shares of the biopharmaceutical company's stock after selling 90,733 shares during the quarter. New York State Teachers Retirement System owned approximately 0.08% of Pfizer worth $116,134,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the company. Horizon Financial Services LLC lifted its stake in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 645 shares during the last quarter. YANKCOM Partnership acquired a new position in Pfizer during the 4th quarter worth about $28,000. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer during the 3rd quarter worth about $29,000. Darwin Wealth Management LLC purchased a new position in Pfizer during the 2nd quarter valued at about $32,000. Finally, True Wealth Design LLC grew its position in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 974 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage trial win for ELREXFIO (elranatamab): Pfizer reported Phase 3 MagnetisMM‑5 results showing a statistically significant improvement in progression‑free survival for relapsed/refractory multiple myeloma, strengthening ELREXFIO’s commercial potential in a high‑value oncology indication. Reuters: Pfizer's blood cancer drug meets main goal in late-stage trial
• Positive Sentiment: VYNDAMAX patent settlement extends US protection to 2031: Pfizer reached settlements with multiple generics makers that effectively push off generic entry for its tafamidis franchise, protecting an asset Reuters and industry reports estimate is worth several billion in annual sales. This preserves a key revenue stream. Yahoo Finance: Pfizer reaches settlement to extend VYNDAMAX patent protection
• Positive Sentiment: FDA accepted sBLA for PADCEV (priority review): Pfizer and Astellas announced the US FDA accepted a supplemental Biologics License Application for PADCEV, advancing a potential label expansion that could add to oncology revenues if approved. InsiderMonkey: Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings preview and estimates: Analysts and services are focused on Pfizer’s May 5 Q1 report; consensus (Zacks) currently forecasts ~$13.8B in sales and $0.74 EPS, so results that deviate from these metrics could move the stock. Zacks: Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Neutral Sentiment: Market positioning and product markets: Reports note Pfizer’s participation in growing OTC markets (e.g., dry‑eye drops) and ongoing analyst coverage that highlights mixed sentiment — positive for pipeline progress but cautious on near‑term growth. Yahoo Finance: $4+ Billion OTC Dry Eye Drops Market Analysis
• Negative Sentiment: Competitive pressure from Alnylam’s Amvuttra: Alnylam’s strong Q1 beat and a near‑200% move for its heart‑disease drug underscore competitive dynamics in certain cardiometabolic portfolios — a reminder that product launches by peers can affect market share and sentiment in overlapping indications. Yahoo Finance: Alnylam surges after its Pfizer‑rivaling blockbuster jumps nearly 200%
• Negative Sentiment: Minor analyst estimate tweaks: Erste Group made a very small FY2027 EPS trim, and some analysts express mixed views — not a large revision but a headwind if further downgrades occur ahead of earnings. (No link)

Pfizer Trading Up 1.8%

Shares of NYSE:PFE opened at $26.75 on Friday. Pfizer Inc. has a 52 week low of $21.97 and a 52 week high of $28.75. The company's 50 day moving average is $27.17 and its two-hundred day moving average is $26.09. The company has a market cap of $152.08 billion, a PE ratio of 19.67 and a beta of 0.43. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company's revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.63 earnings per share. Equities analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio is currently 126.47%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on PFE shares. Daiwa Securities Group lowered shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price target on the stock. in a research note on Thursday, February 12th. Morgan Stanley raised their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research note on Friday, April 10th. HSBC lifted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, March 17th. Citigroup increased their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday. Finally, Cantor Fitzgerald reissued a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus target price of $28.74.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.